WO2025024400A3 - Tryptamines substituées et leurs utilisations - Google Patents
Tryptamines substituées et leurs utilisations Download PDFInfo
- Publication number
- WO2025024400A3 WO2025024400A3 PCT/US2024/039061 US2024039061W WO2025024400A3 WO 2025024400 A3 WO2025024400 A3 WO 2025024400A3 US 2024039061 W US2024039061 W US 2024039061W WO 2025024400 A3 WO2025024400 A3 WO 2025024400A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- aspects
- tryptamines
- methods
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente divulgation concerne, selon certains aspects, certaines tryptamines substituées, telles que des tryptamines contenant une substitution 2,7-dialkyle ou 2-halo-7-alkyle sur le cycle indole. L'invention concerne également des procédés de synthèse des composés, des compositions contenant les composés, et des procédés d'utilisation des composés et des compositions. Selon certains aspects, les caractéristiques des composés comprennent une activité neuromodulatrice, par exemple, l'activation de récepteurs de la sérotonine. Dans certains autres aspects, les composés sont utiles en tant qu'agents thérapeutiques, tels que des agents anti-inflammatoires.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363528259P | 2023-07-21 | 2023-07-21 | |
| US63/528,259 | 2023-07-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2025024400A2 WO2025024400A2 (fr) | 2025-01-30 |
| WO2025024400A3 true WO2025024400A3 (fr) | 2025-03-06 |
Family
ID=94375683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2024/039061 Pending WO2025024400A2 (fr) | 2023-07-21 | 2024-07-22 | Tryptamines substituées et leurs utilisations |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2025024400A2 (fr) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2870162A (en) * | 1954-04-28 | 1959-01-20 | Upjohn Co | Production of certain tryptamines and compounds produced in the process |
| US20200030309A1 (en) * | 2016-09-29 | 2020-01-30 | The Regents Of The University Of California | Compounds for increasing neural plasticity |
| US20220096504A1 (en) * | 2019-01-30 | 2022-03-31 | Diamond Therapeutics Inc. | Methods and compositions comprising a 5ht receptor agonist for the treatment of psychological, cognitive, behavorial, and/or mood disorders |
| US20220251040A1 (en) * | 2019-02-27 | 2022-08-11 | The Regents Of The University Of California | N-substituted indoles and other heterocycles for treating brain disorders |
| US11660305B2 (en) * | 2019-11-19 | 2023-05-30 | Turtle Bear Holdings, Llc | Tryptamine compositions for enhancing neurite outgrowth |
-
2024
- 2024-07-22 WO PCT/US2024/039061 patent/WO2025024400A2/fr active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2870162A (en) * | 1954-04-28 | 1959-01-20 | Upjohn Co | Production of certain tryptamines and compounds produced in the process |
| US20200030309A1 (en) * | 2016-09-29 | 2020-01-30 | The Regents Of The University Of California | Compounds for increasing neural plasticity |
| US20220096504A1 (en) * | 2019-01-30 | 2022-03-31 | Diamond Therapeutics Inc. | Methods and compositions comprising a 5ht receptor agonist for the treatment of psychological, cognitive, behavorial, and/or mood disorders |
| US20220251040A1 (en) * | 2019-02-27 | 2022-08-11 | The Regents Of The University Of California | N-substituted indoles and other heterocycles for treating brain disorders |
| US11660305B2 (en) * | 2019-11-19 | 2023-05-30 | Turtle Bear Holdings, Llc | Tryptamine compositions for enhancing neurite outgrowth |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2025024400A2 (fr) | 2025-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0593513T3 (da) | Tryptaminanaloger, deres syntese og deres anvendelse som 5-HT,-lignende eller 5-HT2-receptoragonister | |
| ATE423769T1 (de) | Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten | |
| BG106539A (en) | Bicyclic androgen and progesterone receptor modulator compounds and methods | |
| MX2021001690A (es) | Indoles sustituidos y metodos de uso de los mismos. | |
| TW200718424A (en) | Novel compounds of amino sulfonyl derivatives | |
| MY155036A (en) | Quinolinone-carboxamide compounds as 5-ht4 receptor agonists | |
| MY143367A (en) | Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases | |
| NZ208529A (en) | 2-pyrimidinyl-1-piperazine derivatives and pharmaceutical compositions | |
| BR0311593A (pt) | Derivados de 1-sulfonil-4-aminoalcoxi indol como moduladores de receptor 5-ht6 para tratamento dos distúrbios de snc | |
| NO20061845L (no) | Fenyl-piperazinderivater som modulatorer for muskarine reseptorer | |
| MX2023010316A (es) | Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos. | |
| MX2007011695A (es) | Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos. | |
| ATE307133T1 (de) | Hexahydroazepino(4,5-g)indole und -indoline als 5-ht-rezeptor-liganden | |
| MX2025002166A (es) | Compuestos y metodos para modular her2 | |
| WO2025024400A3 (fr) | Tryptamines substituées et leurs utilisations | |
| MX2007011698A (es) | Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos. | |
| EA202190322A1 (ru) | ИМИДАЗО[1,2-b]ПИРИДАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ TRK | |
| MX2025002501A (es) | Derivados de indolina como agentes serotoninérgicos útiles para el tratamiento de trastornos relacionados con los mismos | |
| WO2022204344A3 (fr) | N-oxydes d'énamine : synthèse et application à des promédicaments sensibles à l'hypoxie et agents d'imagerie | |
| MXPA05013256A (es) | Derivados de 1-(alquilaminoalquil-pirolidin-/piperidinil) -2,2-difenilacetamida como antagonistas de receptores muscarinicos. | |
| CA3156320A1 (fr) | Derives de 2-azaspiro[3,4] octane utilises en tant qu'agonistes de m4 | |
| WO2024081961A3 (fr) | Analogues d'ester de psilocine, leurs procédés de préparation et procédés d'utilisation | |
| MX2022004215A (es) | Derivados de 2-azaespiro[3.4]octano como agonistas de m4. | |
| WO2025019454A3 (fr) | Ergolines substituées | |
| FI932996A0 (fi) | Heterocykliska foereningar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 24846340 Country of ref document: EP Kind code of ref document: A2 |